During the past decade, Wuhan Pulmonary Hospital conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Wuhan Pulmonary Hospital" are "COVID-19" (3 trials). Many other conditions were trialed in "Wuhan Pulmonary Hospital" in a lesser frequency.

Most popular intervention types in "Wuhan Pulmonary Hospital" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Favipiravir" (2 trials), "Anluohuaxian" (1 trials), "Favipiravir Combined With Tocilizumab" (1 trials) and "Tocilizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Wuhan Pulmonary Hospital" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Wuhan Pulmonary Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Wuhan Pulmonary Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Wuhan Pulmonary Hospital, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".